GSK, Moderna and mRNA vaccine
Reuters · 2d
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
pharmaphorum · 1d
GSK turns its guns on Moderna in mRNA jab patent dispute
The Mandl team was originally employed by Novartis, but GSK acquired rights to their work and intellectual property when it acquired Novartis' global vaccine business in 2015. Only by tapping into this earlier work was Moderna able to bring its mRNA vaccines to market so swiftly, the suits claim.
FiercePharma · 2d
GSK takes mRNA patent fight to Moderna, suing over vaccines for COVID and RSV
Nearly six months after lodging a similar complaint against Pfizer and BioNTech over the partners’ COVID shot Comirnaty, GSK is targeting Moderna in a pair of lawsuits alleging the Massachusetts-ba | GSK is targeting Moderna in a pair of lawsuits claiming the mRNA specialist violated multiple patents with its vaccines Spikevax and mRESVIA.
Reuters · 1d
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
The Global Legal Post · 1d
GSK sues Moderna over Covid and RSV vaccines
GSK filed two lawsuits at the US District of Delaware on 15 October saying that Moderna’s mRNA vaccine product Spikevax infringed up to seven patents covering lipid mRNA vaccine formulation technology. It is also suing Moderna for infringing the same mRNA technology through the sale of its recently approved RSV shot mResvia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results